Drug Safety

      APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA
      ✅ ACR20: 67–68% vs 47% (PBO)
      ✅ ↓radio

      Mrinalini Dey DrMiniDey

      4 months 1 week ago
      APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA ✅ ACR20: 67–68% vs 47% (PBO) ✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35) No new safety signals identified. @RheumNow #EULAR2025 #LB0010 https://t.co/LLN1TXvOC3
      #GameChanger

      Subset analysis of #CTD Pts with
      Progressive pulmonary fibrosis
      #PPF
      Ok background #nintedanib 1/3
      ❎lun

      Janet Pope Janetbirdope

      4 months 1 week ago
      #GameChanger Subset analysis of #CTD Pts with Progressive pulmonary fibrosis #PPF Ok background #nintedanib 1/3 ❎lung IS 2 doses #PDE4Bi #nerandomilast vs #PBO each dose ⬇️worsening #FVC vs PBO ⬇️lung events - hospital ⬇️death GI A/E #EULAR2025 Latebreakers I @RheumNow https://t.co/PWKEnpyyMN
      Management and prognosis of RP by @Lupusreference
      1. Pts with mild disease respond to GCs
      2. NSAIDs/colchicine good alt

      Adela Castro AdelaCastro222

      4 months 1 week ago
      Management and prognosis of RP by @Lupusreference 1. Pts with mild disease respond to GCs 2. NSAIDs/colchicine good alternatives 3. Most common biologics used: TNFi and IL6i 4. Consider CYP in life threatening dz/ICU pts 5. Dynamic CT assess tracheal collapse. 6. PET-CT can ≠ https://t.co/PNUecMZvkT
      Results from open label
      extension of BE-OPTIMAL:
      -Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y un

      Adela Castro AdelaCastro222

      4 months 1 week ago
      Results from open label extension of BE-OPTIMAL: -Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y until 3y. -No significant major tolerability issues or major SE. abstract #POS1294 #EULAR2025 @RheumNow https://t.co/VAEiciCR1z
      ICI-PMR irAEs are sometimes underestimated compared to inflamm arthritis, but why?

      ICI-IA and ICI-PMR look different, b

      David Liew drdavidliew

      4 months 1 week ago
      ICI-PMR irAEs are sometimes underestimated compared to inflamm arthritis, but why? ICI-IA and ICI-PMR look different, but at @HSpecialSurgery, steroid needs and disease impact for both are basically the same. Let’s not devalue either @lovetolearn27 #EULAR2025 POS1200 @RheumNow https://t.co/NVq2tpjvdu
      #EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-specific ab in dose escalation showed rapid & B-cell depletion & all achieved SRI-4. No =>G2 CRS or ICANS. USP: off-the-shelf & overcome T-cell exhaustion @RheumNow https://t.co/6DZRj09JEQ
      LEVI-04 (neutrophin-3 inhibitor presented as #ACR24 late-breaker in knee OA)
      more good efficacy data, no rapidly progres

      David Liew drdavidliew

      4 months 1 week ago
      LEVI-04 (neutrophin-3 inhibitor presented as #ACR24 late-breaker in knee OA) more good efficacy data, no rapidly progressive OA safety signal. For us clinicians: impressive impact size, esp relative to alternatives. Finally, something that works?? #EULAR2025 OP0374 @RheumNow https://t.co/iVdlwyaqrv
      acr_session2.jpeg
      EULAR 2025 – Day 3 Report
      4 months 2 weeks ago
      Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.
      In 631 axSpA pts (mean age 33y, 54% female) from DESIR cohort, high-dose NSAID use (ASAS NSAID index ≥50) not associat

      Antoni Chan MD (Prof) synovialjoints

      4 months 2 weeks ago
      In 631 axSpA pts (mean age 33y, 54% female) from DESIR cohort, high-dose NSAID use (ASAS NSAID index ≥50) not associated with incident hypertension (HR 1.01; 95% CI 0.98–1.02) over 72 months. NSAID anti-inflammatory effect may offset BP risk in axSpA. Abstract#POS0256 @RheumNow https://t.co/ELYWoJDyKJ
      #Shingrix #vaccination is Impt in #SLE
      HZ vaccination works in SLE, safe – 1yr still good humeral & cellular immun

      Janet Pope Janetbirdope

      4 months 2 weeks ago
      #Shingrix #vaccination is Impt in #SLE HZ vaccination works in SLE, safe – 1yr still good humeral & cellular immunity -attenuation over 1 yr re #immune #responses No major flares #shingles is ⬆️ in #lupus 👇 abnormal immune response #pred, #MMF #IS POS1005 #EULAR2025 @RheumNow https://t.co/o8lDXgOhE1
      How does #HCQ work in #SLE

      Stabilizes lysomal membranes?

      #Lupus pts on HCQ monoRx & low #SLEDAI were followed

      Si

      Janet Pope Janetbirdope

      4 months 2 weeks ago
      How does #HCQ work in #SLE Stabilizes lysomal membranes? #Lupus pts on HCQ monoRx & low #SLEDAI were followed Single cell seq HCQ cytokine sigs May vary over time IFN & OXPosph pathways #Hydroxychloroquine in #LN - #IFN I&II #EULAR2025 @RheumNow POS0983 https://t.co/0gMQh9MNlg
      #TDM for #HCQ warns of #toxic #levels in #CRF

      v low GFR <30, <60, <90, >90
       
      400mg/d all in low GFR toxic

      Janet Pope Janetbirdope

      4 months 2 weeks ago
      #TDM for #HCQ warns of #toxic #levels in #CRF v low GFR <30, <60, <90, >90   400mg/d all in low GFR toxic   200mg/d 25% in low GFR toxic   6mg/kg/d – low GFR is too ⬆️ adjust HCQ dose for pts with CRF POS0987 #EULAR2025 @RheumNow @eular_org https://t.co/vg2b87LuiE
      1/3 of #ERA pts poor
      Outcomes despite controlled disease!
      2 #RCT with T2T in early #RA
      #CARERA
      👇
      persistent impact

      Janet Pope Janetbirdope

      4 months 2 weeks ago
      1/3 of #ERA pts poor Outcomes despite controlled disease! 2 #RCT with T2T in early #RA #CARERA 👇 persistent impact ⬆️TJC, comorbidities ⬇️SJC, CRP, global, HAQ,  F>M ⬆️disease durat’n ▶️ ⬆️ b/tsDMARDs despite =diseaese vs others ?overRx OP0330 #EULAR2025 @RheumNow @eular_org
      Procalcitonin can be used in the monitoring of infection, but is also high in Stills disease. 89 AOSD pts showed pts w h

      Dr. John Cush RheumNow

      4 months 2 weeks ago
      Procalcitonin can be used in the monitoring of infection, but is also high in Stills disease. 89 AOSD pts showed pts w high PCT had more pleuritis, MAS,^LFTs, & correlated w/ Dz activity, CRP, LDH, hi ferritin & normalized w bDMARD Rx. #EULAR2025 abstr #POS1118 https://t.co/NpRA9optd3
      ALTO: Long-term Outcomes of APIPPRA
      4 months 2 weeks ago

      Catch up on Conference Podcasts

      ×